MOREPENLAB
Morepen Laboratories Limited (MOREPENLAB) Stock Analysis
Morepen Laboratories Limited is an Indian pharmaceutical and OTC company known for home diagnostics, APIs, and formulations in chronic and acute therapies. It markets Dr. Morepen consumer health devices alongside medicines. Domestic brand presence and exports support growth. It is listed on Indian stock exchanges.
Healthcare › Drug Manufacturers - Specialty & Generic
₹129.60
-3.12% 1W | +173.90% 52W
Market Cap
7.1k CR
P/E Ratio
50.6
52W High
₹150.7
52W Low
₹33
Div. Yield
0.15%
Beta
0.9
50 DMA
₹105.5
200 DMA
₹59.4
Profit Margin
7.2%
Inst. Own.
1.5%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401 | 422 | 445 | 423 | 455 | 438 | 453 | 466 | 425 | 412 | 484 | 485 | 570 |
| Expenses | 375 | 388 | 394 | 375 | 404 | 394 | 417 | 424 | 401 | 381 | 438 | 460 | 488 |
| Operating Profit | 26 | 34 | 51 | 48 | 52 | 44 | 36 | 42 | 24 | 31 | 46 | 24 | 83 |
| OPM % | 7% | 8% | 11% | 11% | 11% | 10% | 8% | 9% | 6% | 7% | 10% | 5% | 14% |
| Other Income | 2 | 3 | 4 | 4 | 3 | 5 | 5 | 5 | 4 | 30 | 4 | 8 | 5 |
| Interest | 0 | 0 | 2 | 1 | 1 | 1 | 1 | 5 | 4 | 4 | 4 | 4 | 5 |
| Depreciation | 8 | 8 | 8 | 10 | 6 | 2 | 5 | 16 | 9 | 11 | 10 | 6 | 8 |
| Profit before tax | 21 | 29 | 44 | 42 | 48 | 46 | 35 | 26 | 16 | 46 | 35 | 23 | 75 |
| Tax % | 29% | 26% | 27% | 32% | 25% | 24% | 24% | 21% | 26% | 10% | 22% | 33% | 24% |
| Net Profit | 15 | 21 | 32 | 29 | 36 | 35 | 27 | 20 | 11 | 41 | 28 | 16 | 56 |
| EPS in Rs | 0.29 | 0.42 | 0.63 | 0.55 | 0.71 | 0.64 | 0.49 | 0.37 | 0.20 | 0.75 | 0.50 | 0.29 | 1.03 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 401 | 485 | 595 | 607 | 769 | 853 | 1,188 | 1,547 | 1,418 | 1,690 | 1,812 | 1,806 | 1,951 |
| Expenses | 352 | 424 | 534 | 542 | 701 | 785 | 1,070 | 1,410 | 1,338 | 1,532 | 1,638 | 1,680 | 1,767 |
| Operating Profit | 48 | 62 | 61 | 65 | 68 | 69 | 119 | 137 | 80 | 159 | 174 | 126 | 184 |
| OPM % | 12% | 13% | 10% | 11% | 9% | 8% | 10% | 9% | 6% | 9% | 10% | 7% | 9% |
| Other Income | 1 | -3 | 4 | 4 | 4 | 9 | 12 | 10 | 6 | 14 | 18 | 47 | 48 |
| Interest | 9 | 10 | 8 | 4 | 2 | 2 | 2 | -7 | 2 | 4 | 8 | 16 | 17 |
| Depreciation | 39 | 35 | 34 | 34 | 40 | 37 | 30 | 28 | 28 | 33 | 29 | 36 | 36 |
| Profit before tax | 2 | 13 | 24 | 30 | 29 | 39 | 99 | 127 | 56 | 135 | 155 | 120 | 179 |
| Tax % | 6% | -1% | 0% | 0% | 1% | 14% | 1% | 20% | 31% | 29% | 24% | 20% | |
| Net Profit | 2 | 13 | 24 | 30 | 29 | 34 | 97 | 102 | 39 | 97 | 118 | 96 | 141 |
| EPS in Rs | 0.05 | 0.28 | 0.53 | 0.66 | 0.64 | 0.75 | 2.16 | 2.13 | 0.76 | 1.88 | 2.15 | 1.73 | 2.57 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 9% | 12% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 8.0% | 9.0% | 14.0% |
| Profit CAGR | 18.0% | -8.0% | 14.0% |
Shareholding Pattern
Promoters35.66%
FIIs1.62%
DIIs1.49%
Public61.22%
Promoters35.66%
FIIs1.62%
DIIs1.25%
Public61.46%
Promoters35.66%
FIIs1.59%
DIIs1.25%
Public61.50%
Promoters35.66%
FIIs1.46%
DIIs1.28%
Public61.59%
Promoters35.66%
FIIs3.43%
DIIs1.70%
Public59.19%
Promoters38.22%
FIIs0.96%
DIIs2.93%
Public57.88%
Promoters38.22%
FIIs1.85%
DIIs2.15%
Public57.76%
Promoters35.66%
FIIs1.94%
DIIs1.67%
Public60.72%
Promoters35.66%
FIIs1.59%
DIIs1.25%
Public61.50%
Promoters35.66%
FIIs3.43%
DIIs1.70%
Public59.19%
MOREPENLAB
Holdings Analysis
Key strengths & risk signals
73
Overall
61
Fundamental
85
Technical
Risks (1)
TOO MUCH PUBLIC HOLDING! 58.45% public ownership - higher volatility risk.
Strengths (4)
FAIRLY VALUED! PEG of 1.45 indicates reasonable valuation.
BULLISH TREND! 50-day average (105.5) is above 200-day average (59.4) - positive signal.
EXCELLENT YEAR! Stock gained 173.9% in the last year.
BULLISH SENTIMENT! In last 30 days: 18 up days, 12 down days. Avg volume on up days: 25,161,947 vs down days: 15,646,597. Ratio: 1.61x
Fundamental & Technical Analysis
73Overall
61Fundamental
85Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 8.4% (MODERATE, 8/15). Profit CAGR: 34.9% (EXCELLENT, 15/15).
Profit Margin
3/10
LOW MARGIN! 7.2% profit margin - thin profits.
PEG Valuation
9/10
FAIRLY VALUED! PEG of 1.45 indicates reasonable valuation.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.15% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 58.45% public ownership - higher volatility risk.
Stability Index
8/10
GOOD STABILITY! Only 1 revenue dip in history. Strong business fundamentals.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (105.5) is above 200-day average (59.4) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (129.6) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 173.9% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 18 up days, 12 down days. Avg volume on up days: 25,161,947 vs down days: 15,646,597. Ratio: 1.61x
RSI
3/5
NEUTRAL! RSI at 57.9 - balanced momentum.
52W Range
5/5
STRONG! Trading at 82.1% of 52W range - near yearly highs.
Momentum
3/5
MIXED MOMENTUM! Price growth is inconsistent - -3.1% (1 week), 11.2% (1 month), 111.6% (3 months).
Beta
4/5
BELOW MARKET! Beta of 0.90 - slightly less volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MOREPENLAB | ₹129.60 | 50.6 | 7.2% | 8.4% | 34.9% | +173.9% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| BLISSGVS | ₹656.00 | 52.1 | 13.5% | 7.2% | 22.1% | +328.1% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| AARTIPHARM | ₹855.50 | 36.4 | 10.4% | -2.6% | -3.3% | +5.7% | 56 | CONSOLIDATING UP | +65.4% | +24.5% | +38.7% | -8.0% |
| INNOVACAP | ₹1,110.00 | 41.2 | 8.8% | 20.1% | 27.5% | +37.7% | 76 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| SUVEN | ₹282.80 | – | – | -19.3% | – | +45.9% | 55 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| SPARC | ₹185.60 | 3.8 | 83.0% | -45.3% | – | +46.8% | 58 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
| IOLCP | ₹201.20 | 35.2 | 6.7% | 1.6% | -0.4% | +101.6% | 62 | CONSOLIDATING UP | +90.0% | +21.1% | +37.1% | +22.1% |
| PGHL | ₹5,205.00 | 24.2 | 24.9% | 8.2% | 19.3% | -15.6% | 76 | BREAKOUT | +45.3% | +1.7% | +7.4% | -1.8% |
Data from TradeAlone · Updated daily
MOREPENLAB News
Morepen Laboratories Limited Submits First U.S. ANDA for Sitagliptin Tablets2026-09-28Morepen Laboratories Limited Q1 FY27: Highest-ever Quarterly Revenue and Earnings2026-08-04Morepen Laboratories Limited (morepenlab) Starts Commercial Supplies Under its ₹825 Crore CDMO Mandate2026-07-01Morepen Laboratories Limited (morepenlab) Q4 FY26: Net Profit Rises 69%; CDMO Program Commences2026-05-27
